Call deadline 20 August 2021. Please find the application form here.
The challenge is to design, develop and evaluate in clinical practice a prototype accessible inspiratory flow resistance device, calibrated for the dry powder inhaler (DPI), aerosol inhalers including metered dose inhalers (MDI) ranges, with inspiratory rate, flow, speed, and resistance measures suitable for remote consultations.
Currently only the In-Check (Clement Clarke patent) device is available to measure internal resistance for inhaled therapies. The In-Check is a handheld device designed for multi-patient use within clinics. Currently In-Check devices are limited in several ways, including not being supplied for personal or remote use to people who use inhaled therapies. The In-Check has an analogue scale, a digital readout would be clearer and easier for people to use and could, with the potential to link with other digital health and care systems, be used in remote consultations. Conversely placebo inhalers are designed to check a person’s inhaler technique against an individual device, and not across multiple devices, a single standardised device with multiple resistance levels could facilitate better targeting of inhaled therapies.
This call is seeking partners to develop a device capable of measuring inspiratory airflow resistance measures in l/min, aligned with DPI and MDI inhaled therapies flow rates and resistance measures, in addition to breath hold time or angle of inhalation. This device should be handheld and portable technology with an accessible (suitable for the visually impaired) digital readout.
Extended scope could incorporate a measure of the angle of inhalation and inspiratory volume. The technology/device needs to be either single patient use, or suitable for regular decontamination between uses. Ideally the technology/device would be capable of connecting to patient records, online self-management applications and online medicinal formularies.
This device if developed could be made available for those people in remote settings but could also be used in pharmacies and in GP practices during annual reviews and prior to prescription and collection of new inhaled medications.
If you have an innovation in this area, then please do get in touch and apply through the application form here. For any further information or queries please contact Robert Hull firstname.lastname@example.org.